Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT — Stella

Home/Stem Cell Transplant Complications/

View on ClinicalTrials.gov

Recruiting

Back to Stem Cell Transplant Complications trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Peking University Institute of Hematology,Beijing, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

Peking University People's Hospital

Enrollment target

~55 participants

Started

September 2018

Primary completion

October 2023

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 55 Years

Last updated March 2020

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.